Post by
mdjbrown on Mar 19, 2024 12:22am
Frustrating that Avicanna's share price has almost
doubled since the beginning of February, while Medipharms share price cant gain a full penny.
Both companies are in a very similiar space, so is it effective marketing on the part of AVCN that is rewarding shareholders?
Comment by
subaru1 on Mar 19, 2024 10:30am
Poor marketing is certainly one of the raison, or they don't have anything to share with us.